Navigation Links
Lilly to Discontinue Development of Tabalumab Based on Efficacy Results in Phase 3 Lupus Studies
Date:10/2/2014

INDIANAPOLIS, Oct. 2, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)  announced today it will discontinue development of tabalumab­ -- being studied for the treatment of systemic lupus erythematosus (SLE, commonly known as lupus) -- due to insufficient efficacy in two pivotal Phase 3 trials. The decision was not based on safety concerns. ­­­­

In the ILLUMINATE 1 study, tabalumab did not achieve the primary endpoint, at either dose studied, of statistically significant improvement on SRI-5 (SLE Responder Index-5, a measurement of lupus disease activity and response), compared to standard of care therapy. In ILLUMINATE 2, the higher dose of tabalumab met this endpoint, the first time a lupus study has achieved this efficacy measure as a primary endpoint in a Phase 3 trial. Collectively, the data from these studies did not meet expectations for efficacy in the context of existing treatments. The overall safety profile showed a similar frequency of adverse events in patients treated with either tabalumab or standard of care. Lilly intends to submit these data for disclosure in appropriate upcoming scientific venues.

Given the overall efficacy results from these two pivotal Phase 3 studies, Lilly will not move forward with submissions to global regulators. Lilly will work with investigators to appropriately conclude these studies in the interest of patient safety.

"Although we were pleased that tabalumab met the criteria for statistically significant improvement in the SRI-5 endpoint in one of our trials, we are nonetheless disappointed that the overall results did not meaningfully improve the condition of the patients in these studies," said J. Anthony Ware, M.D., Senior Vice President, Product Development, Lilly Bio-Medicines. "The ILLUMINATE trials are the largest Phase 3 clinical studies in lupus to date, and we are hopeful that our contribution of the extensive data from these studies will advance knowledge to enhance treatment in this devastating illness. Lilly remains committed to developing potential new medicines for the treatment of autoimmune conditions, including lupus."

The decision to discontinue development of tabalumab for lupus is expected to result in a third-quarter charge to research and development expense of up to $75 million (pretax), or approximately $0.04 - $0.05 per share (after-tax).

About systemic lupus erythematosus (SLE)
Systemic lupus erythematosus (also known as lupus) is a chronic, autoimmune disease that can damage any part of the body (skin, joints, and/or organs inside the body), and can range from mild to life-threatening. The Lupus Foundation of America estimates that up to 1.5 million people in the United States and 5 million people throughout the world have a form of lupus. Lupus strikes mostly women of childbearing age (15-44), though men, children, and teenagers also develop lupus. Most people develop lupus between the ages of 15-44.1

About Eli Lilly and Company (NYSE: LLY)
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels.

P-LLY

This press release contains forward-looking statements about tabalumab as a potential treatment for systemic lupus erythematosus and reflects Lilly's current belief. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

1 Lupus Foundation of America: http://www.lupus.org/answers/entry/what-is-lupus (Accessed September 29, 2014)

Refer to:

Media: J. Scott MacGregor, jsmacgregor@lilly.com, +1-317-440-4699


Investors: Phil Johnson, johnson_philip_l@lilly.com, +1-317-655-6874

 

Logo - http://photos.prnewswire.com/prnh/20031219/LLYLOGO


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Lillys seventh Global Day of Service rallies 24,000 employees in nearly 60 countries
2. Global Breast Cancer Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Company and F. Hoffmann-La Roche, Novartis and Sanofi-Aventis
3. Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine
4. Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimers disease
5. European Commission grants Lilly and Boehringer Ingelheims insulin glargine product marketing authorisation in Europe
6. Lilly Highlights Latest Work in Diabetes Discovery and Development at 2014 European Association for the Study of Diabetes Annual Meeting
7. Global Diabetic Neuropathy Market 2014-2018: Key Vendors are Eli Lilly and Co, Janssen Pharmaceuticals and Pfizer Inc.
8. Lilly Reports Second-Quarter 2014 Results
9. The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune
10. Global Type 1 Diabetes Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Co, Novo Nordisk and Sanofi-Aventis
11. Lilly Announces Acquisition of CGRP Antibody for Migraine Prevention from Arteaus Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2018)... ... 2018 , ... In the world of contract manufacturing, Ion Labs is currently ... has been a game-changing year for Ion Labs . Expansions in the form ... growth. Ion Labs attributes its growth to its responsiveness to customer inquiries, staying in ...
(Date:10/11/2018)... ... October 11, 2018 , ... RevSpring, ... that it has completed the strategic combination of RevSpring and Apex Revenue ... cycle engagement, billing, and payments solutions generating over one billion consumer financial ...
(Date:10/11/2018)... (PRWEB) , ... October 11, 2018 , ... In the ... and Europe in two core families and allowance of six more in USA, China ... at the heart of its MRI safety and security products. , The patents assigned ...
Breaking Medicine Technology:
(Date:10/16/2018)... ... October 16, 2018 , ... Bastyr University is pleased announce ... Health and Medicine’s (AIHM) Visionary Award for his passionate efforts in forging a ... selected as AIHM’s recipient of the Visionary Award due to his tireless effort ...
(Date:10/16/2018)... (PRWEB) , ... October 16, 2018 , ... dicentra Global ... Cannabis Edibles HACCP Certification Program . Canada will become the first G7 country in ... the government of Canada also plans to formally legalize the production and use of ...
(Date:10/16/2018)... (PRWEB) , ... October 16, 2018 , ... ... First Healthcare Compliance, an attorney experienced in employment law, writes frequently on employment ... publications. Recently, she authored a chapter in the Health Care Compliance Professional's Manual ...
(Date:10/16/2018)... ... ... months of training are over. The race has come and gone. It doesn’t matter if ... through the wringer after the big event. Read on for something healthy hints from the ... to treat the body and mind after a long run: , 1. Don’t sit. Walk ...
(Date:10/16/2018)... ... October 16, 2018 , ... ... founded by patient-survivors, and The Avoca Group, Inc., a life sciences consulting ... process, today announced its mutual collaboration that will make Avoca’s industry research ...
Breaking Medicine News(10 mins):